drugset / Trial / NCT00753272

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

NCT00753272 ↗

Phase 3 Completed 43695 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided in two surveillance phases: one passive phase along the study during the influenza season and one active surveillance phase during the influenza peak season.

Timeline

Start
2008-09-15
Primary completion
2010-06-18
Completion
2011-01-05

Outcome

Mixed primary results

paper The coprimary objectives were to assess the relative efficacy of the vaccines and lot-to-lot consistency of the AS03-adjuvanted TIV PMID 23518156 ↗

paper relative efficacy 12·11%, 95% CI -3·40 to 25·29; superiority not established). PMID 23518156 ↗

paper The manufacturing consistency of 3 lots of AS03-TIV was demonstrated. PMID 27690762 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluarix Vaccine — Intramuscular
Subject GSK2186877A Vaccine — Intramuscular

Indications